These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27578108)

  • 1. Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis.
    Stefanutti C; Morozzi C; Di Giacomo S; Sovrano B; Mesce D; Grossi A
    J Clin Lipidol; 2016; 10(4):782-789. PubMed ID: 27578108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
    Roeters van Lennep J; Averna M; Alonso R
    J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.
    D'Erasmo L; Gallo A; Cefalù AB; Di Costanzo A; Saheb S; Giammanco A; Averna M; Buonaiuto A; Iannuzzo G; Fortunato G; Puja A; Montalcini T; Pavanello C; Calabresi L; Vigna GB; Bucci M; Bonomo K; Nota F; Sampietro T; Sbrana F; Suppressa P; Sabbà C; Fimiani F; Cesaro A; Calabrò P; Palmisano S; D'Addato S; Pisciotta L; Bertolini S; Bittar R; Kalmykova O; Béliard S; Carrié A; Arca M; Bruckert E
    Orphanet J Rare Dis; 2021 Sep; 16(1):381. PubMed ID: 34496902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
    Stefanutti C
    Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy.
    D'Erasmo L; Cefalù AB; Noto D; Giammanco A; Averna M; Pintus P; Medde P; Vigna GB; Sirtori C; Calabresi L; Pavanello C; Bucci M; Sabbà C; Suppressa P; Natale F; Calabrò P; Sampietro T; Bigazzi F; Sbrana F; Bonomo K; Sileo F; Arca M
    Adv Ther; 2017 May; 34(5):1200-1210. PubMed ID: 28432645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
    Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
    Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience.
    Sperlongano S; Gragnano F; Natale F; D'Erasmo L; Concilio C; Cesaro A; Golia E; Crisci M; Sperlongano R; Fimiani F; Russo M; Arca M; Limongelli G; Calabrò P
    J Cardiovasc Med (Hagerstown); 2018 Mar; 19(3):83-90. PubMed ID: 29389816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study.
    Nohara A; Otsubo Y; Yanagi K; Yoshida M; Ikewaki K; Harada-Shiba M; Jurecka A
    J Atheroscler Thromb; 2019 Apr; 26(4):368-377. PubMed ID: 30259883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
    Cuchel M; Blom DJ; Averna MR
    Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia.
    Ben-Omran T; Masana L; Kolovou G; Ariceta G; Nóvoa FJ; Lund AM; Bogsrud MP; Araujo M; Hussein O; Ibarretxe D; Sanchez-Hernández RM; Santos RD
    Adv Ther; 2019 Jul; 36(7):1786-1811. PubMed ID: 31102204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study.
    D'Erasmo L; Steward K; Cefalù AB; Di Costanzo A; Boersma E; Bini S; Arca M; van Lennep JR;
    Eur J Prev Cardiol; 2022 May; 29(5):832-841. PubMed ID: 34971394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lomitapide for the management of homozygous familial hypercholesterolemia.
    deGoma EM
    Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience.
    Aljenedil S; Alothman L; Bélanger AM; Brown L; Lahijanian Z; Bergeron J; Couture P; Baass A; Ruel I; Brisson D; Khoury E; Gaudet D; Genest J
    Atherosclerosis; 2020 Oct; 310():54-63. PubMed ID: 32906018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
    Vuorio A; Tikkanen MJ; Kovanen PT
    Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting.
    Mahzari M; Zarif H
    Adv Ther; 2021 May; 38(5):2159-2169. PubMed ID: 33829367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia: an observational case series.
    Suppressa P; Coppola C; Cocco V; O'Brien S
    Orphanet J Rare Dis; 2024 Oct; 19(1):370. PubMed ID: 39380044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
    Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
    Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.
    Averna M; Cefalù AB; Stefanutti C; Di Giacomo S; Sirtori CR; Vigna G
    Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):36-44. PubMed ID: 26723464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Lomitapide in Hypercholesterolemia.
    Liu X; Men P; Wang Y; Zhai S; Zhao Z; Liu G
    Am J Cardiovasc Drugs; 2017 Aug; 17(4):299-309. PubMed ID: 28255870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.